Company: BSX
Filing Date: 2025-03-19
Form Type: DEF 14A
Source: 0000885725-25-000017
Chunk: 54

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-03-19
Form: DEF 14A
Chunk 54
---
.

#### 442025 Proxy Statement

### Compensation Discussion & Analysis
This Compensation Discussion & Analysis section describes material elements of our 2024 compensation program for our named executive officers (NEOs), which includes our Chief Executive Officer (CEO), our Chief Financial Officer (CFO), and our three other most highly-compensated executive officers. NEOs for the yea r ended December 31, 2024 w ere as follows:

| Michael F. Mahoney   |     | Chairman of the Board, President and Chief Executive Officer           |
| Daniel J. Brennan    |     | Executive Vice President and Chief Financial Officer                   |
| Arthur C. Butcher    |     | Executive Vice President and Group President, MedSurg and Asia Pacific |
| Joseph M. Fitzgerald |     | Executive Vice President and Group President, Cardiology               |
| Jeffrey B. Mirviss   |     | Executive Vice President and President, Peripheral Interventions       |

#### Executive Summary
Strategic Imperatives Linked to 2024 Executive Compensation

During 2024, our management team continued to execute on our category leadership strategy, focusing on innovation and diversification, and enhancing our capabilities for the future. To keep with our commitment to pay for performance, the Compensation Committee set ambitious but achievable targets based on our internal plan, reflecting relevant internal and external factors, with a goal of motivating employees to drive stockholder value. In 2024, we achieved outstanding financial performance, surpassing our financial goals set for the year, while positioning the Company well for the year ahead and for the future. We are proud of our global team, their focus on our core mission and values, and their unwavering commitment to supporting our customers and their patients.

In setting our compensation program goals for the year, the Compensation Committee continued to focus on empowering employees to execute on our strategic imperatives, help drive innovation, improve the quality of healthcare of all patients across the globe, accelerate profitable revenue growth, and increase stockholder value in 2024. These strategic imperatives are to:

#### •

#### execute on our category leadership strategy;
• expand into high growth adjacencies that complement our core businesses;

#### •

#### drive global expansion;
• fund the journey to fuel growth through optimization and cost reduction initiatives and a reallocation of spending to support growth initiatives; and

• develop and expand key capabilities, including attracting and retaining key talent, and accelerating digital capabilities.

We believe that continued focus on these strategic imperatives will benefit patients and customers and lead to